Research programme: cancer therapeutics - Merck/Piramal Healthcare

Drug Profile

Research programme: cancer therapeutics - Merck/Piramal Healthcare

Alternative Names: Cancer therapeutics - Merck/Piramal Healthcare; TargetY

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Merck & Co; Piramal Life Sciences
  • Developer Merck & Co; Piramal Enterprises
  • Class Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India
  • 15 Jun 2012 Preclinical trials in Cancer in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top